Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Withdrawn Not applicable Interventional

A Performance Evaluation of the Enlite 3 Sensor

NCT02649010
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Enlite 3 Sensor
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
14 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Walnut Creek, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

NCT00001249
View directory record Official record
Conditions
Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous
Interventions
Yttrium-90 radiolabeled anti-Tac antibody
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 4 Interventional

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

NCT00340613
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glargine insulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes

NCT05540704
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders, Disordered Eating Behaviors, Purging (Eating Disorders), Binge-Eating Disorder
Interventions
ACT, Supportive Diabetes Counseling
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 50 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

NCT03199638
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
Interventions
Glutamine vs. Placebo, Exercise
Drug · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM

NCT00760526
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Continuous glucose monitor, Home blood glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 9 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of an Insulin Sensitivity-Informed Bolus Calculator in Type 1 Diabetes

NCT03709108
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SI-Informed Bolus Calculator
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes

NCT04082884
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Very Low Carbohydrate Diet
Behavioral
Lead sponsor
Yale University
Other
Eligibility
13 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

NCT02411578
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tablets
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Mylan Insulin Aspart Study

NCT03760068
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1601D Product, FlexPen NovoLog®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
158
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression

NCT00021788
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
islet cell transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2010 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting

NCT03241212
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years to 21 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

NCT00442767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Pramlintide + Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes

NCT01209312
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bolus timing and dosing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 13, 2026, 7:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VX-264
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

NCT00665145
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Placebo
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
La Jolla, California • Walnut Creek, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

NCT04326257
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab+Relatlimab, Nivolumab+Ipilimumab
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

NCT05696366
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sotagliflozin, Volagidemab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk

NCT05701254
View directory record Official record
Conditions
Type 1 Diabetes, Osteopenia, Bone Loss, Fractures, Bone
Interventions
Transilial bone biopsy
Procedure
Lead sponsor
Creighton University
Other
Eligibility
50 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Behavioral Family Therapy and Type One Diabetes

NCT03720912
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Online Learning Modules
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Not listed Not applicable Interventional

Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

NCT04720170
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Revascularization
Procedure
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 7:33 PM EDT